Source link : https://www.newshealth.biz/health-news/fda-grants-livdelzi-accelerated-approval-for-pbc/
The US Food and Drug Administration (FDA) granted accelerated approval for Livdelzi(seladelpar, Gilead Sciences, Inc.) for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who fail to respond adequately to UDCA, or as monotherapy in those who can’t tolerate UDCA. Livdelzi, a selective agonist of peroxisome proliferator–activated receptor delta, is not […]
Author : News Health
Publish date : 2024-08-14 20:08:51
Copyright for syndicated content belongs to the linked Source.
Categories